Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E A Surwit

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Gynecologic Oncology|June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trialG R Weiss, S Green, E V Hannigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1987
Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group StudyD S Alberts, R Kronmal, L H Baker, et al.
American Journal of Clinical Oncology|June 1, 1991
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group StudyD D Von Hoff, S Green, D S Alberts, et al.
Cancer|June 15, 1988
Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival durationS M Lippman, D S Alberts, D J Slymen, et al.
Preventive Medicine|September 1, 1989
The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trialsP M Plezia, D S Alberts, Y M Peng, et al.
Gynecologic Oncology|March 1, 1995
Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervixA V Hallum, D S Alberts, S M Lippman, et al.
Gynecologic Oncology|January 1, 1989
Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group StudyD S Alberts, N Mason-Liddil, R V O'Toole, et al.
Gynecologic Oncology|January 1, 1989
Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group StudyD S Alberts, N Mason-Liddil, R V O'Toole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancerD S Alberts, S Green, E V Hannigan, et al.
Cancer|January 15, 1993
Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group studyD S Alberts, S Dahlberg, S J Green, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Gynecologic Oncology|June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trialG R Weiss, S Green, E V Hannigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1987
Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group StudyD S Alberts, R Kronmal, L H Baker, et al.
American Journal of Clinical Oncology|June 1, 1991
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group StudyD D Von Hoff, S Green, D S Alberts, et al.
Cancer|June 15, 1988
Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival durationS M Lippman, D S Alberts, D J Slymen, et al.
Preventive Medicine|September 1, 1989
The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trialsP M Plezia, D S Alberts, Y M Peng, et al.
Gynecologic Oncology|March 1, 1995
Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervixA V Hallum, D S Alberts, S M Lippman, et al.
Gynecologic Oncology|January 1, 1989
Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group StudyD S Alberts, N Mason-Liddil, R V O'Toole, et al.
Gynecologic Oncology|January 1, 1989
Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group StudyD S Alberts, N Mason-Liddil, R V O'Toole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancerD S Alberts, S Green, E V Hannigan, et al.
Cancer|January 15, 1993
Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group studyD S Alberts, S Dahlberg, S J Green, et al.
Pageof 9